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Objectives: Patients with Parkinson’s disease are frequently treated with levo-
dopa which treats stiffness and tremors. Many patients develop problems with 
involuntary movements called ‘dyskinesia’ as a result of levodopa medication. 
Levodopa-induced dyskinesia (LID) can be improved by adjusting the dosage to 
find a tolerable balance between the benefits and side effects. LID fluctuates in 
severity throughout the day but there is no reliable way of objectively monitoring 
patients at home. The intervention is ClearSky’s LID-Monitor which demonstrates 
the severity of involuntary movements in relation to drug doses, enabling clini-
cians to make informed decisions regarding altering complex drug regimens. The 
objective of this study was to assess the cost effectiveness of implementing LID-
Monitor in patients presenting with dyskinesia. MethOds: An early stage cost 
effectiveness model was developed from an NHS perspective. The decision tree 
model examined implementation of LID-Monitor compared to current practice 
over one year. The model considers the incident population, the proportion of 
patients that are well-controlled or poorly-controlled, the number of falls, health-
care resource use and utility associated with dyskinesia. The model inputs were 
derived from published literature and clinical expert opinion. Due to the high 
level of uncertainty, extensive sensitivity analyses were conducted. Results: 
The results estimated that implementing LID-Monitor resulted in a dominant 
ICER and a NMB of over £84 million for the whole of England. The costs saved as 
a result of reducing consultations, reducing hospital monitoring and reducing 
the number of falls outweighed the cost of implementing LID-Monitor. Patients 
also benefitted from an increase in QALYs with an average incremental QALY of 
0.13 per patient per year. Sensitivity analysis showed that results were dominant 
in all plausible scenarios. cOnclusiOns: The model shows that implementing 
ClearSky’s LID-Monitor in UK hospitals has the potential to reduce costs to the 
NHS and increase patients’ quality of life.
PMD81
Early StagE EconoMic Evaluation of carEtoy SyStEM for Early 
intErvEntion in PrEtErM infantS at riSk of nEuroDEvEloPMEntal 
DiSorDErS
Manetti S1, Cecchi F1, Sgandurra G2, Cioni G2, Laschi C1, Dario P1, Turchetti G1
1Scuola Superiore Sant’Anna, Pisa, Italy, 2IRCCS Fondazione Stella Maris, Pisa, Italy
Objectives: To preliminary assess the economic impact of CareToy, the innovative 
technological smart modular system for early intervention (EI) in preterm infants 
at risk of neurodevelopmental disorders. The incidence of preterm births (before 
than 37 weeks of gestational age) has increased and survival rates in very preterm 
infants have improved over the past two decades. EI has been used in the clinical 
setting with the aim of improving the overall outcome for preterm infants and the 
CareToy project – funded by the European Commission within the FP7 – has devel-
oped and validated the CareToy system as a new technological tool for an intensive, 
individualized, home-based and family-centred EI in preterm infants. MethOds: A 
decision tree model was developed in order to assess the likely cost-effectiveness 
of the innovative tele-rehabilitation system in comparison with the Standard of 
Care (SoC) to treat preterm infants at risk from a neurodevelopmental perspective. 
In addition to the data collected by the Randomized Controlled Trial (RCT) study 
within the CareToy project, a structured search was carried out to identify evidence 
of relevant facts concerning clinical outcomes, costs and effectiveness in order 
to populate the entire model. It should be stressed that a small amount of litera-
ture evidence on current treatments in the EI field was to date available. Results: 
The decision model provided the tools to measure the innovation of the CareToy 
system in health economic terms. cOnclusiOns: An advantageous collaboration 
among technology developers, physicians and assessors of innovations is essential 
for improving the efficiency of taking innovative biomedical technologies through 
the Early Health Technology Assessment (EHTA) process and into adoption in the 
healthcare practice.
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Objectives: We developed a cost-effectiveness model for inflammatory arthritis 
(IA) patients who were suspected of having rheumatoid arthritis (RA), and ana-
lysed the simulated costs and effectiveness of different diagnostic test strate-
gies. MethOds: A decision tree to classify patients as true positive, false positive, 
true negative, and false negative, followed by a patient-level state transition model 
was developed. Disease progression was modelled as changes in disease activity 
(DAS28) over time, which were linked to costs and health-related quality of life 
obtained from a usual care IA cohort and an early RA trial. We modelled that an 
earlier diagnosis would improve early treatment, which in turn would reduce DAS28 
by 0.2, thereby postponing the start of biologic treatment. Three new diagnostic test 
strategies (add-on for all patients, add-on for intermediate-risks, and replacement) 
evaluating four different tests (B-cell, MRI, IL-6 serum levels and genetic assay) 
were compared with the ACR/EULAR 2010 RA classification criteria representing 
the current test strategy. The time horizon was 5 years. Probabilistic sensitivity 
analyses, headroom analyses, and exploratory univariate sensitivity analyses were 
performed. Results: A B-cell test (sensitivity: 0.60, specificity: 0.90, costs: € 150) was 
the most cost-effective test in all three strategies. MRI (sensitivity: 0.90, specificity: 
0.60, costs: € 756) and IL-6 (sensitivity: 0.70, specificity: 0.53, costs: € 50) test were 
less cost-effective mainly due to higher costs of MRI (€ 756) and lower specificity 
of IL-6 (0.53). When using a QALY willingness-to-pay threshold of € 30,000, genetic 
assay (sensitivity: 0.40, specificity: 0.85, costs: € 750) is not cost-effective in any of 
the strategies. cOnclusiOns: We have shown that our model is able to assess the 
cost-effectiveness of different diagnostic test strategies including the consequences 
for treatment decisions and disease course, and can easily be used for any new test 
for the early diagnosis of RA.
ADAb-screening as compared to no screening. MethOds: A literature-informed 
decision tree model with 1-year time horizon was used for moderate-to-severe RA 
patients who failed 1stTNF-α blocker from a United States payer perspective. The 
model consisted of two alternatives as ADAb screening or non-screening. In ADAb 
screening arm, there was test positive or test negative branches. Each screening 
result included the probability of receiving a 2nd TNF-α blocker or non-TNF bio-
logic. Each treatment resulted in a likelihood of response or failure. Response was 
defined as an improvement of 28-joint count Disease Activity Score > 1.2 units. The 
pathway of non-screening was similar to ADAb-screening, but with screening naïve 
probabilities of treatment and response/failure. Results: Over 1 year treatment 
period, ADAb-screening was more costly but more effective than no screening. 
Patients who received ADAb-screening had 82.0% chance of treatment response with 
an average of $28,218, while patients who did not get screened had 78.5% chance of 
treatment response with an average of $28,053. The incremental response was 3.5% 
with additional cost as $164. The incremental cost-effectiveness ratio was $4,641 
per additional responder. cOnclusiOns: ADAb-screening increases the likelihood 
of response in moderate-to-severe RA patients and slightly increases overall cost 
of RA treatment. Uncertainty in this analysis could be reduced with prospective or 
observational analyses.
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Objectives: The Cancer Cell Progression (CCP ) score is a validated genomic assay 
that assesses risk of prostate cancer−specific disease progression and mortality 
when combined with standard clinic-pathologic parameters to identify patients at 
low / very low risk of progression who are candidates for treatment abstention and 
surveillance. This study assesses the cost-effectiveness of the use of the CCP score 
versus actual risk-stratification practice in France in making treatment decisions 
for men diagnosed with low risk prostate cancer. MethOds: A Markov model was 
designed comparing treatment decisions based on diagnosis with and without the 
CCP score in men with localised low risk cancer prostate. Short term benefits were 
the number of radical treatments avoided at diagnosis. Expected long term ben-
efits were avoiding delayed curative treatments for patients misdiagnosed as low 
risk, according to standard criteria. Direct medical costs were considered and were 
identified through public data sources. Transition probabilities, mortality rates and 
utilities were derived from a literature review. Costs and benefits were discounted at 
a 4% rate. Results: The use of the CCP score at the time of diagnosis led to a 41 % 
reduction of the number of initial ablative treatments. The test generated an extra 
cost varying between € 12 and € 644, according to different price assumptions. In the 
long term, at a hypothetical price of € 2,000, using the test was a dominant strategy, 
with lower lifetime discounted costs of € 1,709 and an incremental discounted QALY 
gain of 0.23. cOnclusiOns: The information provided by the test has the potential 
to reduce the number of unnecessary invasive treatments for low risk patients. 
Overall, the use of CCP score leads to cost savings and an improved quality of life 
by avoiding the side effects of more radical therapy.
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Objectives: The clinical effectiveness of Motiva Monitor platform was established 
in the previous study (TEN-HMS). Patients randomly assigned to receive Usual 
Care had higher one year mortality (45%) than patients assigned to receive Nurse 
Telephone Support (27%) or Home Telemonitoring (29%) (p= 0.032). Our intention is to 
provide insights in the cost-effectiveness of Motiva telehealth system by modeling 
the intervention and running the analysis on top of the reported data. MethOds: 
Effectiveness was established by mining the EuroQol-5D from the original database, 
while the information on costs came from the literature and the manufacturer of the 
equipment. Direct healthcare costs considered ER visits, GP, Specialist, Hospitalist 
and Nurse time and resources utilization. The induced (indirect) costs were not con-
sidered in the analysis. The approximation of the cost of medical consumption came 
from the Netherlands only, although the original study was run in three European 
countries. We assumed the payer perspective for our analysis. Results: The results 
clearly show, within the parameters of our model, the increased effectiveness of 
Home Telemonitoring and Nurse Telephone Support in comparison to the Usual 
Care. The deterministic results show ICERs of € 14.842 and € 12.547 per QALY (dis-
counted at 1.5% a year) for HTM and NTS respectfully. Probabilistic results show that 
NTS was the most effective strategy in health systems that pay more than € 12.500 
per QALY. In the subgroup analysis HTM dominated both NTS and UC at the thresh-
old of € 16.500 in NYHA IV group of Chronic Heart Failure patients. cOnclusiOns: 
Home telemonitoring by Motiva Monitor system reduces mortality and lowers the 
in-hospital length of stay. On the quality of life dimensions, Home Telemonitoring 
was similarly effective as the Nurse Telephone Support, but with more costs. The 
cost-effectiveness analysis shows that both NTS and HTM dominate the Usual Care 
at WTP of € 15.000.
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